Top Gene Interactions
- Metabolism: Hepatic. Four metabolites have been identified in human urine which together account for approximately 15% of an oral dose. The metabolites have antimicrobial activity, but are less active than unchanged ciprofloxacin. Route of Elimination: Approximately 40 to 50% of an orally administered dose is excreted in the urine as unchanged drug. Half Life: 4 hours
- Uses/Sources: For the treatment of the following infections caused by susceptible organisms: urinary tract infections, acute uncomplicated cystitis, chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections (used in combination with metronidazole), infectious diarrhea, typhoid fever (enteric fever), uncomplicated cervical and urethral gonorrhea, and inhalational anthrax (post-exposure).
- Health Effects: Inflammation of the skin (exfoliative dermatitis)
- Symptoms: The major adverse effect seen with use of is gastrointestinal irritation, common with many antibiotics.
- Route of Exposure: Eye contact; parenteral (intravenous injection); oral. Rapidly and well absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability is approximately 70% with no substantial loss by first pass metabolism.
Mechanism of Action
|Target Name||Mechanism of Action||References|
|Potassium voltage-gated channel subfamily H member 2||
DNA topoisomerase 2-alpha
|The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.||
Ciprofloxacin Interacts with Diseases
|Disease||Inference Score||References/Inference Genes|
|Radiation Injuries, Experimental||18.65|
|HIV Wasting Syndrome||17.8|
|Alcoholic liver cirrhosis||17.32|
|Diabetes Mellitus, Experimental||17.04|